A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China

Patient Characteristics, Treatment Patterns, and Resource Usage in Children Diagnosed With Central Precocious Puberty (CPP) in China

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05341128

Acronym

PACTURE

Enrollment

1477

Registered

2022-04-22

Start date

2023-12-13

Completion date

2025-08-27

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Precocious Puberty

Keywords

Central Precocious Puberty

Brief summary

The main purpose is to describe how many children were treated during 24 months or less because of CPP and how treatment worked for them. There are no participants in this trial, the study only involves reviewing participants medical past and current records and collecting information.

Detailed description

This is an observational, non-interventional, retrospective study to evaluate the participants characteristics, current treatment patterns and resource usage in Chinese pediatric participants diagnosed with CPP. This study will enroll approximately 1000 participants. The data available in an existing data source the Chinese CPP Big Data Platform database will be analyzed. All the participants will be assigned to a single observational cohort: • Pediatric Participants With CPP This multi-center trial will be conducted in China. The overall duration of the study will be approximately 3 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

• Participants diagnosed with CPP and treated with GnRHa from the centers participating in this study within the Chinese CPP Big Data Platform database since 2015 to 2024. CPP diagnosis is based on the clinical assessment and description by CPP specialized doctors.

Exclusion criteria

* Not received GnRHa as the treatment for CPP. * No available data for analysis.

Design outcomes

Primary

Measure	Time frame
Percentage of Participants With CPP Treatment	Up to approximately 10 years

Secondary

Measure	Time frame
Percentage of Participants With CPP Treatment at Baseline	At Baseline
Percentage of Participants With Luteinizing hormone (LH) Suppression	Baseline up to approximately 10 years
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)	Up to approximately 10 years

Countries

China

Contacts

STUDY_DIRECTORStudy Director

Takeda

Outcome results